<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176863</url>
  </required_header>
  <id_info>
    <org_study_id>IG1104</org_study_id>
    <nct_id>NCT02176863</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome</brief_title>
  <acronym>FORCE</acronym>
  <official_title>A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, placebo-controlled, double-blind, parallel
      group clinical trial with adaptive dose selection in subjects with post polio syndrome (PPS).

      The main purpose of this study is to select a dose of Flebogamma 5% DIF and confirm the
      efficacy of the selected Flebogamma® 5% DIF dose by assessing physical performance, as
      measured by 2 Minutes Walk Distance (2MWD) test.

      The study will consist of 2 stages, with each stage consisting of a screening period (up to 4
      weeks), a treatment period (52 weeks), and a follow-up period (24 weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II/III multicenter, prospective, randomized, placebo-controlled,
      double-blind, parallel‑group clinical trial with an adaptive design (flexible group
      sequential design with adaptive dose selection) in subjects with PPS.

      This study will consist of two stages. The first stage (Stage 1) is for dose selection, and
      the second stage (Stage 2) is to establish the superiority (efficacy confirmation) of
      Flebogamma 5% DIF and for overall safety analysis. Stage 1 is a 3-arm evaluation of 2 dose
      levels of Flebogamma 5% DIF. Flebogamma 5% DIF 2 g/kg of body weight (IVIG 2 g/kg arm),
      Flebogamma 5% DIF 1 g/kg of body weight plus the equivalent volume of Normal Saline Solution
      (20 mL/kg of body weight) (IVIG 1 g/kg arm), or a total dose of 40 mL/kg of body weight
      Normal Saline Solution (equivalent volume of the 2 g/kg of body weight Flebogamma 5% DIF
      infusions) (placebo arm) will be administered over 2 consecutive days every 4 weeks during a
      52-week treatment period. At the end of Stage 1, an interim analysis will be conducted and 1
      of the 2 Flebogamma 5% DIF doses will be selected based on predefined criteria to be used for
      Stage 2.

      Stage 2 will consist of 2 treatment arms, the selected dose of Flebogamma 5% DIF from Stage 1
      and Normal Saline Solution (40 mL/kg of body weight). Study drug will be administered over 2
      consecutive days every 4 weeks during a 52-week treatment period. During Stage 2, the
      selected dose of Flebogamma 5% DIF and Normal Saline Solution will be administered in the
      same manner as in Stage 1, including administering the total dose for both treatment arms at
      a volume equivalent to that for the IVIG 2 g/kg arm, regardless of the selected dose.

      Primary efficacy endpoint will be:

        -  Physical performance (2MWD) from baseline to the end of the treatment period (at End of
           Treatment Visit -Week 52).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 2MWD</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Physical performance (2MWD) from baseline (at Enrollment Visit) to the end of the treatment period</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Post-polio Syndrome</condition>
  <arm_group>
    <arm_group_label>Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flebogamma 5% DIF 2 g/kg body weight administered via intravenous infusion over 2 consecutive days (1 g/kg infused on Day 1 and 1 g/kg infused on Day 2) every 4 weeks for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flebogamma 5% DIF 1 g/kg body weight administered via intravenous infusion on Day 1 every 4 weeks for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Arm 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline Solution of matching volume, administered via intravenous infusion either over 1 day or 2 consecutive days every 4 weeks for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Arm 1: Flebogamma 5% DIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of Flebogamma® 5% DIF selected from Stage 1 will be administered every 4 weeks over 2 consecutive days during a 52-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Arm 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A total dose of 40 mL/kg of body weight of Normal Saline Solution will be administered over 2 consecutive days (20 mL/kg infused on Day 1 and 20 mL/kg infused on Day 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flebogamma 5% DIF</intervention_name>
    <description>Human plasma-derived immunoglobulin</description>
    <arm_group_label>Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_label>Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_label>Stage 2 Arm 1: Flebogamma 5% DIF</arm_group_label>
    <other_name>immune globulin intravenous (human)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Stage 1 Arm 3: Placebo</arm_group_label>
    <arm_group_label>Stage 2 Arm 1: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Body Mass Index less than 35 kg/m^2.

          -  Subjects meet March-of-Dimes clinical criteria for diagnosis of PPS.

          -  Subjects who are ambulatory or are able to walk with a cane or other aids or use a
             wheelchair (but they are not wheelchair-bound).

          -  Subjects who have at least 2 newly weakened muscle groups due to PPS (as defined by
             medical history), with at least 1 of them in a lower extremity, and having an Medical
             Research Council (MRC) scale score greater than 3 at the MMT performed by the
             independent assessor at the Screening Visit (SV).

          -  Female of child-bearing potential must have a negative test for pregnancy.

          -  Female of child-bearing potential and their sexual partners have agreed to practice
             contraception using a method of proven reliability.

          -  Subjects who are able to walk a 2MWD of at least 50 meters at the SV and Enrollment
             Visit/Infusion Visit 1 (EV/IV1)

          -  Subjects who are able to walk a consistent baseline 2 MWD, that is, the difference in
             2MWD between the SV and EV/IV1 is not more than 10%.

        Exclusion Criteria:

          -  Subjects have received human normal immune globulin treatment given by intravenous,
             subcutaneous, or intramuscular route within the last 3 years.

          -  Subjects who are not ambulatory (wheelchair-bound individuals).

          -  Subjects with poor venous access.

          -  Subjects with intractable pain requiring narcotics or other psychotropic drugs.

          -  Subjects with a history of anaphylactic reactions or severe reactions to any
             blood-derived product.

          -  Subjects with a history of intolerance to any component of the investigational
             products, such as sorbitol.

          -  Subjects receiving corticosteroids, except for those who are taking inhaled
             corticosteroids for asthma.

          -  Subjects with a documented diagnosis of hyperviscosity or hypercoagulable state or
             thrombotic complications to polyclonal intravenous immunoglobulin (IVIG) therapy in
             the past.

          -  Subjects with a history of recent (within the last year) myocardial infarction,
             stroke, or uncontrolled hypertension.

          -  Subjects who suffer from congestive heart failure, embolism, or electrocardiogram
             changes indicative of unstable angina or atrial fibrillation.

          -  Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in the
             preceding 12 months prior to the SV.

          -  Subjects with active psychiatric illness that interferes with compliance or
             communication with health care personnel.

          -  Subjects with depression with scores &gt;30 as assessed by the Center for Epidemiologic
             Studies Depression validated scale.

          -  Females who are pregnant or are nursing an infant child.

          -  Subjects with any medical condition which makes clinical trial participation
             unadvisable or which is likely to interfere with the evaluation of the study treatment
             and/or the satisfactory conduct of the clinical trial according to the Investigator's
             judgment.

          -  Subjects currently receiving, or have received within 3 months prior to the SV, any
             investigational medicinal product or device.

          -  Subjects who are unlikely to adhere to the protocol requirements, or are likely to be
             uncooperative, or unable to provide a storage serum/plasma sample prior to the first
             investigational drug infusion.

          -  Subjects with known selective IgA deficiency and serum antibodies anti-IgA.

          -  Subjects with renal impairment (i.e., serum creatinine exceeds more than 1.5 time the
             upper limit of normal [ULN]).

          -  Subjects with aspartate aminotransferase or alanine aminotransferase levels exceeding
             more than 2.5 times the ULN.

          -  Subjects with hemoglobin levels &lt;10 g/dL, platelets levels &lt;100,000/mm^3, white blood
             cells count &lt;3.0 k/µL, and erythrocyte sedimentation rate &gt;50 mm/h or twice above
             normal.

          -  Subjects with known seropositive to Hepatitis C virus, Human immunodeficiency virus-1
             and/or Human immunodeficiency virus-2.

          -  Subjects with a history of intolerance to fructose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marinos Dalakas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinating Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Camprubi</last_name>
    <email>sandra.camprubi@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Rucker</last_name>
    <email>karen.rucker@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Cabral</last_name>
      <phone>562-304-1742</phone>
      <email>annecabral@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>Omid Omidvar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine-Deparment of Neurology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khema R. Sharma, MD</last_name>
      <phone>305-243-5586</phone>
      <email>ksharma@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pedro Figueredo</last_name>
      <phone>(305) 243-8829</phone>
      <email>pfigueredo@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Khema R Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raisy Feyerman</last_name>
      <phone>212-342-4447</phone>
      <email>rf2632@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leidy Johana Gonzalez</last_name>
      <phone>212-305-6035</phone>
      <email>ljg2162@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Brannagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammed Iqbal</last_name>
      <phone>315-464-1814</phone>
      <email>iqbalmuh@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jenny Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Roberts, CRC</last_name>
      <phone>215-503-7605</phone>
      <email>aaron.roberts@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gillian Hewitt, CCRP</last_name>
      <phone>215 503 3166</phone>
      <email>Gillian.Hewitt@Jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marinos Dalakas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Lucy</last_name>
      <phone>802-656-4582</phone>
      <email>shannon.lucy@med.uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Rup Tandan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Barkhaus, MD</last_name>
      <phone>414-805-5224</phone>
      <email>pbarkhaus@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marie Mejaki</last_name>
      <phone>4149550624</phone>
      <email>mmejaki@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Barkhaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute Clinical Research Unit, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Faille, PhD</last_name>
      <phone>+1 5143981688</phone>
      <email>catherine.faille@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Daria Trojan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinicko-farmakologická jednotka</name>
      <address>
        <city>Praha</city>
        <zip>4</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiri Skopek, MD</last_name>
      <phone>+420261082567</phone>
    </contact>
    <investigator>
      <last_name>Jiri Skopek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitets Hospital-Neurologisk Forskning</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte G Odgaard</last_name>
      <phone>+45 23 88 25 83</phone>
      <email>charodga@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Louise Hansen</last_name>
      <email>loshas@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Henning Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier, Hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerie Driss</last_name>
      <phone>33467332339</phone>
      <email>v-driss@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Laffont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Montpellier</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elise Elrezzi</last_name>
      <phone>33320446891</phone>
      <email>elise.elrezzi@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Triffeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Fischer</last_name>
      <phone>'+49 511 532-8333</phone>
      <email>fischer.chantal@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Susanne Petri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Grosskreutz, MD</last_name>
      <phone>+49 3641 9323488</phone>
      <email>julian.grosskreutz@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Julian Grosskreutz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für konservative Orthopädie und des Poliozentrums</name>
      <address>
        <city>Koblenz</city>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Ruetz, MD</last_name>
      <phone>+49 261 496 6329</phone>
      <email>A.Ruetz@kk-km.de</email>
    </contact>
    <investigator>
      <last_name>Klaus-Peter Froehling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfälische Wilhelms-Universität Münster</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Keeren</last_name>
      <phone>+49 251 8344478</phone>
      <email>Susanne.Keeren@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Boentert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoltan Szakacs, MD</last_name>
      <phone>3612121846</phone>
      <email>alvas@t-online.hu</email>
    </contact>
    <investigator>
      <last_name>Zoltan Szakacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Országos Orvosi Rehabilitációs Intézet/ Vegyes Profilú Mozgásszervi Rehabilitációs Osztály</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erzsebet Boros, MD</last_name>
      <phone>+36 30 563 0814</phone>
      <email>e.boros@rehabint.hu</email>
    </contact>
    <investigator>
      <last_name>Erzsebet Boros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orla Hardiman</last_name>
      <phone>+353 18093874</phone>
      <email>hardimao@tcd.ie</email>
    </contact>
    <contact_backup>
      <last_name>Triona Bannerman</last_name>
      <phone>+353 18093869</phone>
      <email>tbannerman@rcsi.ie</email>
    </contact_backup>
    <investigator>
      <last_name>Orla Hardiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)</name>
      <address>
        <city>Verona</city>
        <zip>37124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria C Tozzi</last_name>
      <phone>+390458124289</phone>
      <email>mariachiara.tozzi@aovr.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Laura Bertolasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Amsterdam UMC, Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Voorn, PhD</last_name>
      <phone>+31205668250</phone>
      <email>e.l.voorn@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tamar Gibson</last_name>
      <phone>+31 205667692</phone>
      <email>j.t.gibson@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Frans Nollet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety</name>
      <address>
        <city>Krakow</city>
        <zip>30-820</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Banach</last_name>
      <phone>+48 697 860 728</phone>
      <email>jbanach@medtrials.pl</email>
    </contact>
    <investigator>
      <last_name>Marta Banach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Bielewicz, MD</last_name>
      <phone>+48 504 057 464</phone>
      <email>j.bielewicz@op.pl</email>
    </contact>
    <investigator>
      <last_name>Konrad Rejdak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Sp. z o.o.</name>
      <address>
        <city>Poznan</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piasecka Stryczyńska, MD</last_name>
      <phone>+48 697-333-515</phone>
      <email>kpe@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Piasecka Stryczyńska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Guttman</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Pilar Sainz, MD</last_name>
      <email>mpsainz@guttmann.com</email>
    </contact>
    <investigator>
      <last_name>Enric Portell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus AB Karolinska Universitetssjukhuset i Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristian Borg, MD</last_name>
      <phone>+4686555257</phone>
      <email>kristian.borg@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Erla Sigurdardottir</last_name>
      <phone>+46858583327</phone>
      <email>erla.sigurdardottir@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Kristian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FORCE</keyword>
  <keyword>post-polio syndrome</keyword>
  <keyword>Flebogamma</keyword>
  <keyword>Immune Globulin Intravenous</keyword>
  <keyword>IGIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

